REVELATION BIOSCIENCES, INC. (REVB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 17, 2026, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Revelation Biosc

Original reporting
Published Aug 19, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$REVB
Neutral
high confidence
Mentioned
$REVB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$REVBNeutralLow
01

Why it matters

The filing provides a primary disclosure of a routine equity compensation event with no material financial impact.

02

Market read

Low relevance; typical compensation filing for a micro‑cap biotech.

03

What to watch

Potential future dilution if many such awards are granted, but current size unknown.

Relevance 6/10Novelty 2/10Timing: filing date 2026-08-19

Background

SEC Form 8‑K filing for Revelation Biosciences (ticker REVB) detailing a restricted stock award under its 2021 Equity Incentive Plan.

Company-level read

Ticker impact

$REVBNeutralHigh confidence
Context

Revelation Biosciences filed an 8‑K announcing a new restricted stock award to an employee under its 2021 Equity Incentive Plan.

Expected impact

minimal to none

Evidence & confidence

No financial terms, size, or strategic change disclosed; typical for biotech micro‑caps.

Market effects

None; standard compensation practice in biotech sector.

None; company is US‑based with limited market footprint.

None

Counterpoint

If the grant signals upcoming talent retention ahead of a major trial, it could be a subtle bullish cue.

Key entities

  • Revelation Biosciences, Inc.

    Biotech firm filing the 8‑K.

Related articles

$REVBLow

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 SAN DIEGO – November 5, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developi

$REVBMedAI 8/10

Revelation Aiming for Paradigm Shift in Kidney Disease Care

Revelation Biosciences (REVB) is developing Gemini, a drug candidate for acute and chronic kidney disease, post-surgical infections, and severe burns. The company plans to launch a Phase 2/3 study for acute kidney injury later this year, with completion expected in about two years. CEO James Rolke highlights Gemini's potential to reduce inflammation and prevent scar tissue, citing positive pre-clinical and early clinical results. Revelation aims to submit Gemini for FDA approval if the study mee

$REVBMed

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO – August 6, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innov

$SPGIMed

S&P Global Announces Pricing of Public Offering of $750,000,000 Senior Notes due 2031, $600,000,000 Senior Notes due 2034 and $650,000,000 Senior Notes due 2036

S&P Global (NYSE: SPGI) priced a public offering of $750M, $600M, and $650M in senior notes due 2031, 2034, and 2036, respectively. The notes were priced at yields of 5.635%, 5.814%, and 6.001%. Proceeds will be used for general corporate purposes, including possible acquisitions or debt repayment. The offering is expected to close on November 18, 2026, subject to conditions.

$TPBMedAI 8/10

Why Turning Point Brands Stock Got Socked Today

Turning Point Brands (NYSE:TPB) stock fell 11% after filing a mixed shelf registration with the SEC, indicating plans to raise capital. The company registered various securities, including common and preferred stock, for potential sale. Proceeds will be used for general corporate purposes. Shelf registrations often concern investors due to potential dilution or increased debt.